REFERENCES
- Cervantes-Perez LCP, Toro-Perez LCAH, Rodriguez-Jurado MP, Pulmonary involvement in rheumatoid arthritis, J Ann Med Ass 243, 1715–1719(1980).
- Crystal RG, Bitterman PB, Rennard SL et al., Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract, N Engl J Med 310, 154–166(1984).
- Byrd SL, Case BA, Boulware DW, Pulmonary manifestations of rheumatic disease, Postgrad Med 93, 149–166(1993).
- Doctor L, Snider GL, Diffuse interstitial pulmonary fibrosis associated with arthritis: with comments on the definition of rheumatoid lung disease. Am Rev Respir Dis 85, 413–422 (1962).
- Stahel RA, Gilks WR, Lehmann H-P et al., Third international workshop on lung tumor and differentiation antigens: overview of the results of the central data analysis, Int J Cancer Suppl 8, 6–26 (1994).
- Kohno N, Kyoizumi S, Awaya Y el al., New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6, Chest 96, 68–73 (1989).
- Hamada H, Kohno N, Akiyama M et ai. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia, Chest 101, 858–860 (1992).
- Kohno N, Hamada H, Fujioka S et al. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer, Chest 102, 117–122 (1992).
- Kobayashi J, Kitamura S, KL-6: a serum maker for interstitial pneumonia, Chest 108, 311–315 (1995).
- Kobayashi J, Kitamura S, Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis, Chest 109, 1276–1282 (1996).
- Kohno N, Yokoyama A, Hirasawa Y et al., Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia, Respir Med 91, 558–561 (1997).
- Yokoyama A, Kohno N, Kondo K et al. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CAI9-9 and SLX as serum markers for interstitial pneumonitis, Respirology 3, 199–202(1998).
- Oyama T, Kohno N, Yokoyama A et al., Detection of interstitial pneumonitis complicated in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin, Lung 175, 379–385 (1997).
- Kohno N, Akiyama M, Kyoizumi S et al., Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma, Jpn J Clin Oncol 18, 203–216 (1988).
- Yokoyama A, Kohno N, Hamada H et ai. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis, Am J Respir Crit Care Med 158, 1680–1684 (1998).
- Leung AN, Miller RR, Müller NL, Parenchymal opacification in chronic infiltrative lung diseases: CT-pathologic correlation, Radiology 188, 209–214 (1993).
- Remy-Jardin M, Giraud F, Remy J et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation, Radiology 189, 693–698 (1993).
- Inoue Y, Barker E, Daniloff E et ai, Pulmonary epithelial cell injury and elveolar-capillary permeability in berylliosis, Am J Respir Crit Care Med 156, 109–115 (1997).
- Hirasawa Y, Kohno N, Yokoyama A et al., KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts, Am J Respir Cell Mol Biol 17, 501–507 (1997).
- Kohno N, Awaya Y, Oyama T et al., KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease, Am Rev Respir Dis 148, 637–642 (1993).
- Hamada H, Kohno N, Yokoyama A et ai, KL-6 as a serologic indicator of Pneumocystis carini pneumonia in immunocompromised hosts, Intern Med 37, 307–310 (1998).
- Golden MR, Katz RS, Balk RA et al., The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis, J Rheumatol 22, 1043–1047(1995).
- Saag KG, Kolluri S, Koehnke RK et al., Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities, Arthritis Rheum 39, 1711–1719 (1996).
- Ohosone Y, Okano Y, Kameda H et al., Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis, J Rheumatol 24, 2299–2303 (1997).
- van der Veen MJ, Dekker JJ, Dinant HJ et al., Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis, J Rheumatol 22, 1766–1768 (1995).
- Tomioka H, King TE Jr, Gold-induced pulmonary disease: clinical features, outcome, and differentiation from rheumatoid lung disease, Am J Respir Crii Care Med 155, 1011–1020 (1997).
- Cottin V, Tébib J, Massonnet B et al., Pulmonary function in patients receiving long-term low-dose methotrexate, Chest 109, 933–938 (1996).